EFFECT OF BODY POSITION ON VENTRICULAR CSF METHOTREXATE CONCENTRATIONFOLLOWING INTRALUMBAR ADMINISTRATION

Citation
Sm. Blaney et al., EFFECT OF BODY POSITION ON VENTRICULAR CSF METHOTREXATE CONCENTRATIONFOLLOWING INTRALUMBAR ADMINISTRATION, Journal of clinical oncology, 13(1), 1995, pp. 177-179
Citations number
10
Categorie Soggetti
Oncology
ISSN journal
0732183X
Volume
13
Issue
1
Year of publication
1995
Pages
177 - 179
Database
ISI
SICI code
0732-183X(1995)13:1<177:EOBPOV>2.0.ZU;2-C
Abstract
Purpose: Intralumbar methotrexate is one of the primary therapeutic mo dalities for the prevention and treatment of meningeal leukemia, Howev er, methotrexate distribution to the ventricles is limited and highly variable following intralumbar dosing, and cytotoxic concentrations of methotrexate are not always achieved or sustained in the ventricular CSF. We used a nonhuman primate model to determine the effect of body position on the caudal distribution of an intralumbar dose of methotre xate. Methods: Methotrexate (1.0 mg) was administered by intralumbar i njection to four animals, which were then immediately placed either in an upright sitting position or in a prone position for 1 hour, then u pright. Each animal served as its own control and was studied in each position on at least one occasion. Results: The mean peak ventricular methotrexate concentration was 0.12 mu mol/L (range, 0.091 to 0.20) in animals that were immediately placed upright, compared with 2.81 mu m ol/L (range, 0.21 to 8.9) in animals that remained prone for 1 hour. T he mean area under the concentration-versus-time curves (AUG) was 0.51 mu mol/L.h (range, 0.26 to 1.1) in the upright animals and 12.0 mu mo l/L.h (range, 0.9 to 35.4) in the prone animals, Conclusion: Maintaini ng a prone position for 1 hour after an intralumbar dose increased the peak methotrexate concentration and drug exposure in ventricular CSF. CSF drug distribution following intralumbar therapy can be influenced by body position after the injection. (C) 1995 by American Society of Clinical Oncology.